Elisabeth Operschall

RESPIRE 1: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis

Anthony De Soyza, Timothy R. Aksamit, Tiemo-Joerg Bandel et al. · European Respiratory Journal · 2018 · 182 citations · Full text

RESPIRE 2: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis

Timothy R. Aksamit, Anthony De Soyza, Tiemo-Joerg Bandel et al. · European Respiratory Journal · 2018 · 180 citations · Full text

Economic Burden of Non-Cystic Fibrosis Bronchiectasis in the First Year after Diagnosis from A US Health Plan Perspective

Vijay N. Joish, Monica Spilsbury-Cantalupo, Elisabeth Operschall et al. · Applied Health Economics and Health Policy · 2013 · 75 citations

First Year, Non-cystic Fibrosis Bronchiectasis, Health Economics +12

The RESPIRE trials: Two phase III, randomized, multicentre, placebo-controlled trials of Ciprofloxacin Dry Powder for Inhalation (Ciprofloxacin DPI) in non-cystic fibrosis bronchiectasis

Timothy R. Aksamit, Tiemo-Joerg Bandel, Margarita Criollo et al. · Contemporary Clinical Trials · 2017 · 44 citations · Full text

Ciprofloxacin DPI: a randomised, placebo-controlled, phase IIb efficacy and safety study on cystic fibrosis

Henry L. Dorkin, Doris Staab, Elisabeth Operschall et al. · BMJ Open Respiratory Research · 2015 · 27 citations · Full text